Podium to Practice: ESMO® 2025 – BREAST: DESTINY-Breast05

Podium to Practice: ESMO® 2025 – BREAST: DESTINY-Breast05

Podium to Practice: ESMO® 2025
Explore more from your favourite experts – click their name to access their entire library of content.
Icon Chair Speaker

Chair

Dr. Christine Simmons

Icon Chair Speaker

Speakers

Dr. Christine Brezden-Masley

Dr. Heather McArthur

Studies / Trials Discussed

LBA1 – Trastuzumab deruxtecan (T-DXd) vs trastuzumab emtansine (T-DM1) in patients (pts) with high-risk human epidermal growth factor receptor 2–positive (HER2+) primary breast cancer (BC) with residual invasive disease after neoadjuvant therapy (tx): Interim analysis of DESTINY-Breast05

Studies/trials discussed:

LBA1 – Trastuzumab deruxtecan (T-DXd) vs trastuzumab emtansine (T-DM1) in patients (pts) with high-risk human epidermal growth factor receptor 2–positive (HER2+) primary breast cancer (BC) with residual invasive disease after neoadjuvant therapy (tx): Interim analysis of DESTINY-Breast05
Tagged